{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T09:08:33Z","timestamp":1758272913166},"reference-count":0,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["int j tuberc lung dis"],"published-print":{"date-parts":[[2019,9,1]]},"abstract":"<jats:p><jats:bold>SETTING:<\/jats:bold> Patients with rifampicin-resistant tuberculosis (RR-TB) in the township of Khayelitsha, South Africa, were offered delamanid (DLM) within a decentralised RR-TB treatment programme.<jats:bold>OBJECTIVE:<\/jats:bold> To describe adverse events (AEs) among HIV-positive and negative\n people receiving DLM for RR-TB in a programmatic setting.<jats:bold>DESIGN:<\/jats:bold> Patients were followed up monthly for blood, electrocardiography and clinical monitoring and AEs were assessed for severity grade, seriousness and relationship to DLM.<jats:bold>RESULTS:<\/jats:bold> Fifty-eight patients (55% male;\n median age 35 years, interquartile range [IQR] 28\u201342) started DLM; 46 (79%) were HIV-positive, median CD4 count 173 cells\/mm<jats:sup>3<\/jats:sup> (IQR 70\u2013294). Fifty (86%) patients experienced \u22651 new or worsening AE after starting DLM, most commonly vomiting, QTcB &gt;450 ms and\/or myalgia.\n Serious and\/or severe AEs were experienced by 22 (38%) patients; three HIV-positive patients died (not related to DLM). HIV status was not significantly associated with number (<jats:italic>P =<\/jats:italic> 0.089) or severity\/seriousness (<jats:italic>P =<\/jats:italic> 0.11) of AEs during exposure to DLM. Two (3%) patients had\n DLM withdrawn due to AEs.<jats:bold>CONCLUSION:<\/jats:bold> AEs during RR-TB treatment, both before and during DLM exposure, were common, with relatively few serious\/severe AEs considered related to DLM and no significant association with HIV status. Clinical and electrocardiography monitoring should\n be prioritised in the first two months after starting DLM.<\/jats:p>","DOI":"10.5588\/ijtld.18.0651","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:37:59Z","timestamp":1571186279000},"page":"1017-1023","source":"Crossref","is-referenced-by-count":11,"title":["Adverse events among people on delamanid for rifampicin-resistant tuberculosis in a high HIV prevalence setting"],"prefix":"10.5588","volume":"23","author":[{"given":"J.","family":"Hughes","sequence":"first","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res (MSF), Khayelitsha, Cape Town"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Reuter","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res (MSF), Khayelitsha, Cape Town"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Chabalala","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res (MSF), Khayelitsha, Cape Town"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Isaakidis","sequence":"additional","affiliation":[{"name":"MSF, Southern Africa Medical Unit, Cape Town"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Cox","sequence":"additional","affiliation":[{"name":"Division of Medical Microbiology and the Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Mohr","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res (MSF), Khayelitsha, Cape Town"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3554","container-title":["The International Journal of Tuberculosis and Lung Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/iuatld\/ijtld\/2019\/00000023\/00000009\/art00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T04:45:00Z","timestamp":1572324300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.5588\/ijtld.18.0651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,1]]},"references-count":0,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9,1]]}},"alternative-id":["1027-3719(20190901)23:9L.1017;1-"],"URL":"https:\/\/doi.org\/10.5588\/ijtld.18.0651","relation":{},"ISSN":["1027-3719"],"issn-type":[{"value":"1027-3719","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9,1]]}}}